News
CLYM
13.54
-3.29%
-0.46
Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)
TipRanks · 14h ago
Weekly Report: what happened at CLYM last week (0803-0807)?
Weekly Report · 16h ago
RBC Capital Keeps Their Buy Rating on Climb Bio (CLYM)
TipRanks · 3d ago
Climb Bio price target raised to $25 from $17 at Truist
TipRanks · 3d ago
Climb Bio Price Target Raised to $25.00/Share From $17.00 by Truist Securities
Dow Jones · 3d ago
Climb Bio Is Maintained at Buy by Truist Securities
Dow Jones · 3d ago
Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25
Benzinga · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)
TipRanks · 4d ago
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data
TipRanks · 4d ago
Climb Bio GAAP EPS of -$0.18
Seeking Alpha · 4d ago
Climb Bio reports Q2 EPS (18c), consensus (21c)
TipRanks · 4d ago
*Climb Bio 2Q Loss/Shr 18c >CLYM
Dow Jones · 4d ago
*Climb Bio 2Q Loss $13.5M >CLYM
Dow Jones · 4d ago
Press Release: Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 4d ago
Press Release: Climb Bio Reports Second Quarter -2-
Dow Jones · 4d ago
Climb Bio initiated with an Outperform at RBC Capital
TipRanks · 08/03 10:10
Weekly Report: what happened at CLYM last week (0727-0731)?
Weekly Report · 08/03 09:43
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst
TipRanks · 07/30 16:30
Piper Sandler Keeps Their Buy Rating on Climb Bio (CLYM)
TipRanks · 07/30 11:25
Climb Bio Is Maintained at Outperform by Wedbush
Dow Jones · 07/27 13:13
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.